Rochester, NY 6/11/2009 3:13:48 PM
WFWS "After Market Most Active by Volume -Nasdaq" - Lamar Advertising Company,LAMR - ValueVision Media, Inc.,VVTV - Celgene Corporation,CELG
Lamar Advertising Company - ValueVision Media, Inc. - Celgene Corporation
WFWS "After Market Most Active by Volume -Nasdaq" - Lamar Advertising Company,LAMR - ValueVision Media, Inc.,VVTV - Celgene Corporation,CELG
Lamar Advertising Company,LAMR
After Hours: 17.75 0.00 (0.00%) 4:35PM ET
Last Trade: 17.75
Day's Range: 0.00 - 0.00
52wk Range: 5.35 - 41.00
Volume: 2,239,406
Lamar Advertising Company, together with its subsidiaries, provides outdoor advertising services in the United States, Canada, and Puerto Rico. The company offers outdoor advertising displays, such as billboards, including bulletins, posters, and digital billboards; logo signs; and transit advertising displays. It provides its advertising services to restaurants, retailers, automotive, real estate, health care, gaming, service, hotel and motel, telecommunication, and amusement industries, including entertainment and sports. As of December 31, 2008, the company owned and operated approximately 159,000 billboard advertising displays in 44 states, Canada, and Puerto Rico; approximately 1,100 digital billboard advertising displays in 38 states, Canada, and Puerto Rico; approximately 100,000 logo advertising displays in 19 states and the province of Ontario, Canada; and approximately 29,000 transit advertising displays in 17 states, Canada, and Puerto Rico. The company was founded in 1989 and is headquartered in Baton Rouge, Louisiana.
---
If you are viewing this press release you are obviously interested in making money in the stock market. In todayís market investors need every tool available. WhisperfromWallStreet.com sends FREE alerts to our subscribers on stocks that we feel are ready to move within hours or days. So far in 2009 we have sent 36 stock alerts to our clients and the average price gain has been 88%. To add additional profits to your portfolio please take a minute and sign up for our free alerts. There is no risk to you and you will see just how accurate we are in our alerts.
Investors sign up for our FREE alerts at http://whisperfromwallstreet.com
---
ValueVision Media, Inc.,VVTV
After Hours: 1.47 Down 0.01 (0.68%) 8:00PM ET
Last Trade: 1.48
Day's Range: 0.00 - 0.00
52wk Range: 0.18 - 4.33
Volume: 2,475,723
ValueVision Media, Inc., an integrated multi-channel retailer, markets, sells, and distributes its products directly to consumers through various forms of electronic media. Its principal electronic media activity is its television home shopping business, which uses on-air spokespersons to market brand name and private label consumer products. The company also markets an array of merchandise through its Internet retailing Web sites, ShopNBC.com and ShopNBC.TV, which provide a range of consumer merchandise, including various products being featured in its television programming. It sells jewelry, watches, consumer electronics, housewares, apparel, fashion accessories, cosmetics, health and beauty products, coins and collectibles, seasonal items, and other merchandise through its television network and Internet shopping Web sites. ValueVision Media has strategic alliances with GE Capital Equity Investments, Inc. and NBC Universal, Inc. The company was founded in 1990 and is based in Eden Prairie, Minnesota.
---
Celgene Corporation,CELG
After Hours: 43.55 Up 0.32 (0.74%) 8:00PM ET
Last Trade: 43.2
Day's Range: 0.00 - 0.00
52wk Range: 36.90 - 77.39
Volume: 5,062,547
Celgene Corporation engages in the discovery, development, and commercialization of innovative therapies to treat cancer and immune-inflammatory related diseases primarily in Europe and the United States. Its primary commercial stage products include REVLIMID for the treatment in combination with dexamethasone for multiple myeloma patients, as well as for the treatment of patients with transfusion-dependent anemia; and THALOMID for the treatment in combination with dexamethasone of patients with newly diagnosed multiple myeloma, as well as for the treatment and suppression of cutaneous manifestations of erythema nodosum leprosum. The company also sells ALKERAN for the palliative treatment of multiple myeloma and of carcinoma of the ovary; VIDAZA, which is used for the treatment of various subtypes of MDS; RITALIN that is used for the treatment of attention deficit hyperactivity disorder; and FOCALIN for the treatment of oncology-related disorders. Its development stage products consist of CC-4047, which is in Phase II trials for the treatment of myelofibrosis and multiple myeloma, and in Phase I trials for the treatment of hemoglobinopathies; CC-10015 that is in pre-clinical stage for the treatment of inflammatory diseases; CC-10004, which is in Phase II clinical trials for the treatment of psoriasis, psoriatic arthritis, and inflammatory diseases; JNK CC-930 that is in Phase I trial to treat fibrotic diseases; Amrubicin, which is in Phase III trials for small cell lung cancer treatment; Human umbilical cord blood, a Phase I trials product to treat transplants and hematological disorders; and ACE-011, a Phase II initiated product for multiple myeloma/Bone loss treatment. Celgene Corporation has strategic collaborations with Acceleron Pharma, Inc. for the joint development and commercialization of ACE-011; and GlobeImmune Inc. to develop molecular immunotherapy for the treatment of cancer.
---
Do not invest in these stocks because we mentioned them in this release. We never include our picks in these news releases. This is just to alert you to our service. Our alerts are saved for our subscribers. To receive Alerts on the stock we feel are going to move, sign up for our free alert service.
Visit WhisperfromWallStreet.com to sign up for your FREE subscription or download our free Windows Vista or iGoogle gadget for instant alerts direct to your desktop or iGoogle page.
If you are a public company looking to generate investor awareness for your company please contact us at info@WhisperfromWallStreet.com.
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com 585-301-7700
